What are the recent trends in market size and growth for the panuveitis market?
The panuveitis market size has grown rapidly in recent years. It will grow from $4.05 billion in 2024 to $4.47 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to the prevalence of autoimmune and infectious diseases, the growing use of corticosteroids, the growing adoption of biologics, the rising demand for ophthalmic imaging, and the emerging research investment in infectious causes.
The panuveitis market size is expected to see rapid growth in the next few years. It will grow to $6.58 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to the expanding use of biologic therapies, rising demand for personalized medicine, rising prevalence of uveitis-linked diseases, higher investments in ophthalmic research, and rising disease awareness. Major trends in the forecast period include increasing adoption of biologic therapies, sustained-release drug delivery systems, expansion of personalized medicine approaches, advancements in AI-driven diagnosis & treatment, rise in minimally invasive surgical techniques.
Get Your Free Sample of The Global Panuveitis Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21244&type=smp
How have varous drivers impacted the growth of the panuveitis market?
The rising prevalence of autoimmune disorders is expected to propel the growth of the panuveitis market going forward. Autoimmune diseases arise when the immune system incorrectly targets and damages the body’s own healthy cells and tissues. The rising prevalence of autoimmune diseases is due to factors such as a combination of genetic predispositions, environmental factors such as pollution and dietary changes, and increased exposure to certain infections and stressors that may trigger immune system dysregulation. Autoimmune disorders contribute to advancements in panuveitis treatment by driving research into immune system modulation, as many panuveitis cases are related to autoimmune activity. For instance, in May 2023, according to the University of Oxford, a UK-based research university, autoimmune disorders affect 10% of the world’s population, with 13% of women and 7% of males affected. Therefore, the rising prevalence of autoimmune disorders is driving the growth of the panuveitis market.
What are the primary segments of the panuveitis market?
The panuveitis market covered in this report is segmented –
1) By Type: Infectious Panuveitis, Non-Infectious Panuveitis
2) By Treatment: Pharmacological, Surgical, Phototherapy
3) By Route Of Administration: Oral, Intravitreal, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Infectious Panuveitis: Bacterial Panuveitis, Viral Panuveitis, Fungal Panuveitis, Parasitic Panuveitis
2) By Non-Infectious Panuveitis: Autoimmune-Related Panuveitis, Idiopathic Panuveitis, Drug-Induced Panuveitis
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/panuveitis-global-market-report
Which firms are leading the panuveitis market?
Major companies operating in the panuveitis market are Pfizer Inc., AbbVie, Boehringer Ingelheim International GmbH, Amgen, Teva Pharmaceuticals, Sandoz, Organon group of companies, Zydus Lifesciences Ltd., Mallinckrodt plc, Alvotech, EyePoint Pharmaceuticals Inc., Affibody Medical AB, Alumis Inc., Fujifilm Kyowa Kirin Biologics Co. Ltd., Revolo Biotherapeutics Ltd., Tarsier Pharma, Priovant Therapeutics Inc., Mylan N.V., Clearside Biomedical Inc., pSivida Corp.
How will industry trends affect the trajectory of the panuveitis market?
Major companies in the panuveitis market are focusing on developing advanced slow-release intravitreal injection formulations to improve patient compliance and outcomes. A slow-release intravitreal injection formulation is a drug delivery method that gradually dispenses medication into the eye’s vitreous humor over time, ensuring prolonged therapeutic effects while reducing the need for frequent dosing. For instance, In August 2022, Tarsier Pharma, an Israel-based clinical-stage company, announced the development of TRS02, a potential immunomodulator designed for the treatment of retinal diseases. This innovative therapy aims to address various back-of-the-eye conditions characterized by underlying inflammatory pathologies, such as posterior uveitis (panuveitis) and diabetic macular edema. TRS02 is based on Tarsier’s proprietary technology platform and is currently progressing towards investigational new drug (IND) submission following successful preclinical milestones.
Which geographic trends are shaping the panuveitis market, and which region has the highest market share?
North America was the largest region in the panuveitis market in 2024. The regions covered in the panuveitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Panuveitis Market Report 2025 Offer?
The panuveitis market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Panuveitis is a condition characterized by inflammation affecting all three layers of the uvea including the iris, ciliary body, and choroid inside the eye. If not treated, it can cause pain, and blurred vision, and potentially lead to vision loss. The goal of treatment is to control inflammation, relieve symptoms, and prevent further damage to the eye that could impair vision. Timely intervention is essential to protect eye health and maintain vision.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21244
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
